Document is current
Any future updates will be listed below
-
Authors
Larrayoz, Marta https://orcid.org/0000-0001-6097-8244
Garcia-Barchino, Maria J.
Celay, Jon https://orcid.org/0000-0002-2017-4206
Etxebeste, Amaia https://orcid.org/0000-0003-4408-0981
Jimenez, Maddalen
Perez, Cristina
Ordoñez, Raquel
Cobaleda, Cesar https://orcid.org/0000-0003-3807-9204
Botta, Cirino
Fresquet, Vicente https://orcid.org/0000-0003-1511-8354
Roa, Sergio https://orcid.org/0000-0003-1095-0715
Goicoechea, Ibai https://orcid.org/0000-0002-5329-2225
Maia, Catarina
Lasaga, Miren
Chesi, Marta https://orcid.org/0000-0002-4024-8225
Bergsagel, P. Leif https://orcid.org/0000-0003-1523-7388
Larrayoz, Maria J.
Calasanz, Maria J. https://orcid.org/0000-0002-0374-3008
Campos-Sanchez, Elena
Martinez-Cano, Jorge https://orcid.org/0000-0001-6809-5489
Panizo, Carlos
Rodriguez-Otero, Paula
Vicent, Silvestre https://orcid.org/0000-0002-9457-6881
Roncador, Giovanna
Gonzalez, Patricia
Takahashi, Satoru https://orcid.org/0000-0002-8540-7760
Katz, Samuel G.
Walensky, Loren D.
Ruppert, Shannon M.
Lasater, Elisabeth A.
Amann, Maria
Lozano, Teresa
Llopiz, Diana
Sarobe, Pablo
Lasarte, Juan J. https://orcid.org/0000-0003-1641-3881
Planell, Nuria
Gomez-Cabrero, David
Kudryashova, Olga https://orcid.org/0000-0003-3320-7764
Kurilovich, Anna https://orcid.org/0000-0002-3952-8609
Revuelta, Maria V. https://orcid.org/0000-0002-7922-0713
Cerchietti, Leandro https://orcid.org/0000-0003-0608-1350
Agirre, Xabier https://orcid.org/0000-0002-6558-9560
San Miguel, Jesus https://orcid.org/0000-0002-9183-4857
Paiva, Bruno https://orcid.org/0000-0003-1977-3815
Prosper, Felipe https://orcid.org/0000-0001-6115-8790
Martinez-Climent, Jose A. https://orcid.org/0000-0002-7938-3950
- License Information
-
More Information
Article History
Received: 2 February 2022
Accepted: 9 December 2022
First Online: 16 March 2023
Competing interests
: M.C. has received honoraria from participation in advisory boards from Oncopeptides, Novartis, Janssen and Pfizer; and has licensed intellectual property through Mayo Clinical Ventures 2013-058 ‘Genetically engineered mouse model of MM without LoxP sites (Vk*MycCwoLoxP) and transplantable cell lines’. L.B. has received honoraria from participation in advisory boards from Oncopeptides, Novartis, Janssen and Pfizer; and has licensed intellectual property through Mayo Clinical Ventures 2013-058 ‘Genetically engineered mouse model of MM without LoxP sites (Vk*MycCwoLoxP) and transplantable cell lines’. P.R.-O. has received honoraria from advisory boards from Pfizer, BMS, Janssen, GSK, Kite, Sanofi and Oncopeptides; and honoraria from lectures from GSK, Janssen, BMS, Regeneron, Amgen and Oncopeptides. S.M.R. is an employee of Roche/Genentech. E.A.L. is an employee of Roche/Genentech. M.A. is an employee of Roche, and has patent applications on CD25 monoclonal antibody with relevance to this work: WO/2018/167104 and US20190284287 (filed by Cancer Research Technology Limited and Tusk Therapeutics). M.A. has shares in the companies to which the patent belongs. O.K. is an employee of BostonGene. J.S.M. is a consultant and an advisory board member for (on behalf of his Institution) Amgen, BMS, Celgene, Haemalogix, Janssen, MSD, Novartis, Takeda, Sanofi, Roche, Abbvie, GlaxoSmithKline, Regeneron, SecuraBio and Karyopharm. B.P. reports honoraria for lectures from and membership on advisory boards with Adaptive, Amgen, Becton Dickinson, Bristol Myers Squibb-Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda; unrestricted grants from Bristol Myers Squibb-Celgene, EngMab, Roche, Sanofi and Takeda; and consultancy for Bristol Myers Squibb-Celgene, Janssen, Sanofi and Takeda. J.A.M.-C. reports funding for research from Roche/Genentech, Bristol Myers Squibb-Celgene, Janssen, Priothera and Palleon. A patent on the generation and use of the mouse MM models as immunotherapy platforms, entitled ‘Genetically engineered animal models for multiple myeloma’ (application no. EP22382736.1) was filed on 27 July 2022. The remaining authors declare no competing interests.
